Introduction: Stroke is a leading cause of global morbidity and mortality, with acute ischemic stroke (AIS) accounting for most cases. Despite advancements in reperfusion therapies, many patients do not achieve sufficient reperfusion, necessitating effective neuroprotective interventions. This meta-analysis evaluates the efficacy and safety of Edaravone Dexborneol (ED) compared to standard therapies in AIS treatment.
Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines, including randomized controlled trials (RCTs) investigating ED in AIS. Primary outcomes included Modified Rankin Scale (mRS ≤ 1) at 90 days and changes in National Institutes of Health Stroke Scale (NIHSS) scores. Pooled effect sizes were calculated using random-effects models.
Results: Five RCTs with 2,535 patients (1,263 ED, 1,272 control) were included. ED significantly improved the odds of achieving mRS ≤ 1 at 90 days (OR = 1.47, 95% CI [1.25-1.74], p < 0.00001). While NIHSS score changes at 14 days were not significant (p = 0.35), ED showed significant improvement at 30 days (MD = -1.77, 95% CI [-2.82 to -0.72], p = 0.0009). ED also significantly reduced the risk of hemorrhagic transformation (OR = 0.47, 95% CI [0.24-0.92], p = 0.03) and mortality rates were lower in the ED group but not statistically significant (OR = 0.66, 95% CI [0.41-1.06], p = 0.08, I = 1%).
Conclusion: ED demonstrates significant neuroprotective benefits in AIS by improving functional outcomes and reducing the risk of hemorrhagic transformation. However, further studies with larger sample sizes must confirm these findings and optimize treatment protocols.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00210-025-03950-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fecal microbiota transplantation for vancomycin-resistant Clostridium innocuum infection in inflammatory bowel disease: A pilot study evaluating safety and clinical and microbiota outcome.
J Microbiol Immunol Infect
March 2025
Chang Gung Microbiota Therapy Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Electronic address:
Background: Clostridium innocuum is a vancomycin-resistant pathobiome associated with poor clinical outcomes in inflammatory bowel disease (IBD). In ulcerative colitis (UC), it correlates with reduced remission rates, while in Crohn's disease (CD), it is linked to creeping fat formation and intestinal strictures. Notably, some patients experience refractory or recurrent C.
View Article and Find Full Text PDFEfficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
J Am Coll Cardiol
March 2025
National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S.
View Article and Find Full Text PDFMulti-epitope-based vaccine models prioritization against Astrovirus MLB1 using immunoinformatics and reverse vaccinology approaches.
J Genet Eng Biotechnol
March 2025
Department of Dermatovenereology, Kazakhstan Medical University, Almaty, Kazakhstan, 050016. Electronic address:
Astrovirus MLB1 (HAstV-MLB1) is non-enveloped RNA virus that cause acute gastroenteritis infection. Despite research progress about infection and pathogenesis of HAstV-MLB1, Currently, no vaccine has been developed to effectively combat this pathogen. The current study is based on immunoinformatics and reverse vaccinology approaches to design next-generation, multi-epitope-based vaccine models against HAstV-MLB1.
View Article and Find Full Text PDFRecanalization for Symptomatic Non-acute Intracranial Large Vessel Occlusion: An Observational Study.
J Atheroscler Thromb
March 2025
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital.
Aim: This study investigated the efficacy and safety of endovascular revascularization for symptomatic non-acute atherosclerotic intracranial LVO.
Methods: For non-acute atherosclerotic intracranial large vessel occlusion (LVO), despite aggressive medical treatment, recurrent ischemic stroke or transient ischemic attack related to the occluded artery still occurs repeatedly. This retrospective cohort study included stroke patients with intracranial LVO who received endovascular treatment (EVT), categorized by successful recanalization and the time interval from symptom onset to revascularization (＜30 days vs.
Early Mobilization of Patients in the Intensive Care Unit: A Quality Improvement Evidence-Based Project.
J Dr Nurs Pract
March 2025
Department of Nursing, Aspen University, Denver, CO, USA
At an urban public acute care hospital, a gap existed in the safety and efficacy of early mobilization (EM) of intensive care unit (ICU) patients, with the need for an evidence-based intervention. A literature review revealed that a nurse-driven mobility protocol could safely achieve early mobility in ICU patients. This quality improvement project aims to utilize a nurse-driven mobility protocol to determine its effects on EM of ICU patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!